Background: Pixantrone is an aza-anthracenedione with enhanced, preclinical antitumor activity and reduced cardiotoxicity compared with doxorubicin.
weak topoisomerase binder. It has no iron-binding capacity and does not produce reactive oxygenated species or the cardiotoxic reactive metabolite, doxorubicinol [5] . In preclinical studies, pixantrone was substantially less cardiotoxic than mitoxantrone, yet efficacy in animal tumor models was equivalent or superior [5] . Two randomized studies comparing mitoxantrone (CNOP) to doxorubicin (CHOP) showed mitoxantrone to be inferior but with equivalent cardiotoxicity [6, 7] .
Cumulative cardiotoxicities were not found in phase I/II studies of pixantrone in patients with prior doxorubicin therapy for aggressive B-cell non-Hodgkin lymphoma (NHL). Durable, complete remissions were achieved in late-stage, relapsed or refractory disease [8, 9] . In a phase II study of CPOP (substituting pixantrone for doxorubicin) in patients previously treated with CHOP or CHOP + rituximab (R), the CR/CRu rate was 47% in all patients and 54% in patients with prior rituximab therapy [10] .
The current study compared the efficacy and safety of CPOP-R and CHOP-R as first-line therapy in DLBCL patients. The primary study objective was to use the CR/CRu rate to determine non-inferiority of CPOP-R compared with CHOP-R. Other comparison measures included PFS and OS, duration of response, ORR, time-to-treatment failure (TTF), and comparative safety with an emphasis on cardiac safety.
methods study design
The study was an open-label, multicenter, comparative phase II trial in which patients were randomized 1 : 1 to either CPOP-R or CHOP-R. Tumors were assessed with conventional imaging studies (CT, MRI). PET scans were not required. See supplementary Table S1 , available at Annals of Oncology online for monitoring schedule and parameters. An independent assessment panel (IAP) reviewed imaging and determined disease response. Patients discontinued treatment for disease progression, withdrawal of consent or unacceptable toxic effect. Patients were monitored for up to 36 months after end-of-treatment (EOT) for treatment-associated adverse events (AEs), disease progression, additional lymphoma-directed therapy, and survival.
patients
Eligible patients were at least 18 years old, previously untreated, did not have HIV or a pre-existing indolent lymphoma, and had histologically confirmed CD20 + DLBCL by the REAL/WHO classification. Each patient was required to have at least one target lesion that could be objectively followed bidimensionally. Key inclusion and exclusion criteria are summarized in supplementary Table S2 , available at Annals of Oncology online. The protocol, amendments, and patient informed consent documents were reviewed and approved by institutional review boards or ethics committees at study sites and written informed consent from each patient was obtained before enrollment. This study was registered at ClinicalTrials.gov (NCT00268853).
study treatment
Patients randomized in the study are described in Table 1 . In the experimental arm, pixantrone replaced doxorubicin in the CHOP-R regimen. If determined to be in CR after four cycles, patients were given up to two additional cycles. Four additional cycles were completed by patients with <CR after cycle 4. Information on the pixantrone treatment regimen is included in supplementary Table S1 , available at Annals of Oncology online.
safety assessment
All toxic effects were reported as AEs and rated according to the National Cancer Institute Common Terminology Criteria, Version 3.0. AEs were monitored throughout treatment and follow-up periods until resolution, expectation of no further improvement, or the patient began a non-protocoldirected therapy for NHL. Safety outcomes were measured by an independent data monitoring committee. Cardiac function was assessed by serial troponin T assays and MUGA scan or echocardiogram (ECHO) at pre-treatment baseline, after cycles 2, 4, and 6, at the EOT (occurring 30-37 days after the last administration of the study drug), every 6 months for 1 year following EOT, and at 24 and 36 months following EOT.
statistical methods
Randomization (1 : 1) was stratified by baseline International Prognostic Index (IPI) scores (0-1 versus 2-3 versus 4-5). The primary efficacy end point was the proportion of the intent-to-treat (ITT) population achieving CR/CRu. The difference between CR/CRu rates for the two treatment groups was analyzed using a 95% exact CI. Supportive analyses included ORR, PFS, and OS.
All patients receiving at least one dose of protocol-directed therapy were included in the safety analyses. Safety parameters included AEs and cardiotoxicity. The required total sample size to detect a 15% non-inferiority margin with 80% power was 138 patients per arm. Enrollment of 280 patients was originally planned; however, after 124 patients were randomized the sponsor electively closed enrollment in response to financial constraints and regulatory advisement that this trial could not serve as a registrational study. The statistical analysis plan was not changed, but with Table S5 , available at Annals of Oncology online).
patient disposition
Sixty-one patients were randomized to CPOP-R and 63 to CHOP-R. Fifty-nine of the CPOP-R patients and 63 of the CHOP-R patients received study treatment and constitute the safety population. Study treatment was completed by 74% and 71% of patients in the CPOP-R and CHOP-R safety populations, respectively (supplementary Table S6 , available at Annals of Oncology online).
efficacy CR/CRu was 75% for CPOP-R versus 84% for CHOP-R (Table 2 ) and did not meet criteria for non-inferiority [95% confidence interval (CI) of the difference (−5.4% to 22.8%)].
The CR/CRu rates in PIX203 were consistent across the ITT, histologically confirmed ITT population, and per protocol populations (data not shown). There was no significant difference in CR duration between arms, and the median duration of CR was not reached for either arm (supplementary Table S7 , available at Annals of Oncology online). The ORR was 82% for the CPOP-R arm and 90% for the CHOP-R arm ( Table 2 ). The median PFS was not reached in the CPOP-R arm and was 40 months in the CHOP-R arm (HR = 1.02, 95% CI = 0.60, 1.76, P = 0.934). Twenty-five patients (41%) in the CPOP-R arm and 28 (44%) in the CHOP-R arm experienced progressive disease (PD), death, or received subsequent therapy without documented PD ( Figure 1A) . The median time to PD was not reached for either treatment (HR = 0.68, 95% CI = 0.27, 1.70, P = 0.403) (supplementary Table S8 , available at Annals of Oncology online). The median TTF was not significantly different between arms: 30 months for CPOP-R and 40 months for CHOP-R (HR = 1.07, 95% CI = 0.64, 1.79; P = 0.791). At the time of database closure, 9 of the 17 CPOP-R patients with PD and 20 of the 26 CHOP-R patients with PD were still alive. Median OS was not reached for either treatment arm. OS rates were lower for patients treated with CPOP-R than with CHOP-R (HR = 2.37, 95% CI = 1.07, 5.28, P = 0.029), with more deaths occurring in the CPOP-R arm (N = 18, 30%) than in the CHOP-R arm (N = 9, 14%) ( Figure 1B 
safety and tolerability
The safety population included 59 patients in the CPOP-R arm and 63 in the CHOP-R arm who received at least one dose of study drug. The median number of cycles administered was 8 (range 1-8) in the CPOP-R arm and 6 (range 1-8) in the CHOP-R arm. The time to CR was longer in the CPOP-R arm with a CR/CRu rate after four cycles of 45% compared with 60% in the CHOP-R arm, leading to a higher median number of cycles administered in the CPOP-R arm.
The most common AEs (≥10%) in both treatment arms were general and hematologic disorders (data not shown). Grade 3/4 AEs reported in ≥5% of patients are summarized in Table 3 . The most common grade 3/4 drug-related AEs in both treatment groups were neutropenia, leukopenia, lymphopenia, febrile neutropenia, and anemia. Rates were similar in both treatment arms. To manage neutropenia and leukopenia, 45 CPOP-R patients (76%) and 52 CHOP-R patients (83%) received colony stimulating factors during the study period.
cardiac toxicity
More patients on CPOP-R than on CHOP-R (12 [20%] versus 7 [11%]) had three or more significant comorbidities (supplementary Table S4 , available at Annals of Oncology online and Table 1 ) Similar proportions of patients in both arms had hypertension (56% in CPOP-R versus 52% in CHOP-R) (supplementary Table S5 , available at Annals of Oncology online). Table 4 summarizes all relevant cardiac events that occurred during the treatment period and cardiac events reported to pharmacovigilance during the follow-up period, which is defined as the time from the EOT visit to the end of the study. Despite having a lesser number of significant comorbidities, more patients in the CHOP-R arm had troponin T shifts to a higher toxic effect grade over the course of therapy (Table 4 ). The CHOP-R arm had a larger number of LVEF declines from baseline (declines of ≥10% to <50%, ≥15%, ≥20%) and cases of grade 3 CHF compared with the CPOP-R arm (Table 4) .
discussion CHOP-R is the standard of care in patients with DLBCL but is associated with significant cardiotoxicity, particularly in elderly patients [3] . CPOP, a potentially less cardiotoxic option, was given to patients with aggressive B-cell NHL who had relapsed after CHOP or CHOP-R therapy, and was found to be highly active and adequately tolerated in patients with up to 450 mg/m 2 of prior doxorubicin [10] . This phase II, comparative trial was initiated to assess activity and safety of CPOP-R compared with CHOP-R for first-line therapy in patients with DLBCL.
Efficacy outcomes for CPOP-R (CR/CRu, ORR, PFS, and OS) were similar to those reported in the CHOP-R arm of the GELA study of 60-80-year-old adults with DLBCL with low-tomoderate risk disease by IPI scores [3] . The probability of survival for high-risk patients treated with CPOP-R in PIX203 (69% at 3 years) was similar to that reported for CHOP-R (∼65%) by Coiffier et al. and other large studies that included a CHOP-R arm [3, 11] . However, in this study, OS was Figure 1 . (A) Kaplan-Meier comparison of progression-free survival in the PIX203 intent-to-treat population: Kaplan-Meier plot of progression-free survival for CPOP-R and CHOP-R patients, with number of events ( progressive disease per IAP assessment, additional lymphoma treatment and death), median PFS in months, log-rank P-value, HR, and 95% CI. (B) Kaplan-Meier comparison of overall survival in the PIX203 intent-to-treat population: Kaplan-Meier plot of overall survival for CPOP-R and CHOP-R patients, with number of deaths, median survival in months, log-rank P-value, HR, and 95% CI. unprecedentedly higher for CHOP-R compared with results published by Coiffier et al. [3] . IPI score has been shown to predict survival. Although median survival was not reached for the IPI subgroups in either arm of PIX203, survival appeared similar for patients with baseline IPI scores <3. Among patients with baseline IPI scores ≥3, those who received CHOP-R demonstrated longer OS than CPOP-R patients, surpassing reported, historical survival values for CHOP-R treated patients [3] . The differences in deaths between study arms were observed only in patients who were ≥65 years of age, most of whom also had IPI scores ≥3. Deaths in the CPOP-R arm included 3 patients who died within 30 days of the last dose of study drug, 14 who died during follow-up, and 1 who died following randomization, but before receiving study drug. All deaths in the CHOP-R arm occurred during follow-up. Supplementary Table S10 available at Annals of Oncology online summarizes survival analysis at database closure at 36 months of follow-up. Among patients who relapsed, 20 were alive at end of study follow-up in the CHOP-R arm versus 9 in the CPOP-R arm.
The number, presence, and severity of comorbidities may have an important impact on outcome [12] , but due to the small number of patients, no attempt was made to use a weighted comorbidity score reported in stem cell transplantation. While the study arms were generally well balanced, more CPOP-R patients did have three or four comorbid conditions [12 (20%) CPOP-R patients versus 7 (11%) CHOP-R patients]. For patients with three or more comorbidities, 5 of 12 (42%) CPOP-R patients died compared with 3 of 7 (43%) CHOP-R patients (data not shown).
It appears unlikely that treatment-related toxic effect was responsible for the discrepancy in deaths between the two study arms. Overall rates of treatment-related AEs and serious AEs were similar between study arms. Furthermore, serious cardiac events were more common in the CHOP-R arm, including clinical CHF, declines in LVEF ≥15% and ≥20% from baseline, and elevations in serum troponin T. Supplementary Table S9 , available at Annals of Oncology online summarizes factors examined to determine whether treatment-associated toxic effect was a cause of excess mortality. The excess mortality in the CPOP-R patients occurred within the subgroup of patients aged 65 or over, most of whom had IPI scores ≥3, three or more comorbid conditions, and disease relapse. There was no apparent survival advantage for CHOP-R over CPOP-R in the 11 patients (6 in CPOP-R and 5 in CHOP-R) with IPI scores ≥3 who were under age 65, however, this study was inadequate to determine comparative efficacy.
This phase II trial of CPOP-R versus CHOP-R as first-line therapy in DLBCL was limited by small size and was confounded by an unexplained disparity in survival possibly due to subtle imbalances in comorbidities, an unprecedentedly low death rate in high-risk and elderly patients in the CHOP-R arm and a higher proportion of CHOP-R patients alive in relapse at study closure. The results do demonstrate that CPOP-R is an active regimen with modestly lower response rates than CHOP-R but similar PFS and event-free survival and a lower incidence of severe cardiac events. The trial does not Table 4 . Cardiac events-LVEF decreases from baseline by multigated acquisition scan, development of congestive heart failure and troponin T grade shifts CPOP-R CHOP-R P-value All treated patients with events reported through end of study
Patients with at least a 10% point drop in LVEF compared with baseline and to less than 50% references
